Fresenius Medical Care Awarded Mechanical Circulatory Support Agreement with Premier, Inc. for the Novalung® ECMO System
Fresenius Medical Care (FMS) has secured a national group purchasing agreement with Premier, Inc. for its Novalung ECMO System. The agreement provides Premier's 4,350+ member hospitals and health systems access to pre-negotiated pricing for the system, which is FDA-cleared for long-term extracorporeal membrane oxygenation. The Novalung System pumps and oxygenates blood in patients with acute respiratory or cardiopulmonary failure, offering a portable therapy solution for various clinical settings. This strategic partnership aims to expand access to ECMO solutions nationwide and reinforces FMS's commitment to advancing critical care treatments.
Fresenius Medical Care (FMS) ha ottenuto un accordo nazionale di acquisto di gruppo con Premier, Inc. per il suo Novalung ECMO System. L'accordo offre agli oltre 4.350 ospedali e sistemi sanitari membri di Premier l'accesso a prezzi pre-negoziati per il sistema, che è stato autorizzato dalla FDA per la ossigenazione extracorporea a lungo termine. Il sistema Novalung pompa e ossigena il sangue nei pazienti con insufficienza respiratoria acuta o cardiopolmonare, offrendo una soluzione terapeutica portatile per vari contesti clinici. Questa partnership strategica mira ad ampliare l'accesso alle soluzioni ECMO a livello nazionale e sottolinea l'impegno di FMS per il progresso dei trattamenti di terapia intensiva.
Fresenius Medical Care (FMS) ha asegurado un acuerdo nacional de compra grupal con Premier, Inc. para su Novalung ECMO System. El acuerdo proporciona a los más de 4,350 hospitales y sistemas de salud miembros de Premier acceso a precios pre-negociados para el sistema, que está aprobado por la FDA para la oxigenación extracorpórea a largo plazo. El sistema Novalung bombea y oxigena la sangre en pacientes con fallo respiratorio agudo o cardiopulmonar, ofreciendo una solución terapéutica portátil para diversos entornos clínicos. Esta asociación estratégica tiene como objetivo ampliar el acceso a las soluciones ECMO a nivel nacional y refuerza el compromiso de FMS con el avance de los tratamientos de cuidados críticos.
프레제니우스 메디컬 케어(FMS)는 자신의 노바룽 ECMO 시스템을 위해 프리미어(Premier, Inc.)와 국가 그룹 구매 계약을 체결했습니다. 이 계약은 프리미어의 4,350개 이상의 회원 병원 및 건강 시스템이 이 시스템의 사전 협상된 가격에 접근할 수 있도록 합니다. 이 시스템은 FDA에서 장기 체외막 산소화에 대해 승인되었으며, 급성 호흡기 또는 심폐 기능 부전 환자의 혈액을 펌프질하고 산소를 공급합니다. 다양한 임상 환경을 위한 휴대 가능한 치료 솔루션을 제공합니다. 이 전략적 파트너십은 국가적으로 ECMO 솔루션에 대한 접근을 확대하고 FMS의 중환자 치료 개선에 대한 약속을 강화하는 것을 목표로 하고 있습니다.
Fresenius Medical Care (FMS) a obtenu un accord national d'achat de groupe avec Premier, Inc. pour son Novalung ECMO System. Cet accord donne aux plus de 4 350 hôpitaux et systèmes de santé membres de Premier accès à des prix pré-négociés pour le système, qui est approuvé par la FDA pour l'oxygénation extracorporelle à long terme. Le système Novalung pompe et oxygène le sang chez les patients souffrant d'insuffisance respiratoire aiguë ou cardiopulmonaire, offrant une solution thérapeutique portable pour divers environnements cliniques. Ce partenariat stratégique vise à élargir l'accès aux solutions ECMO à l'échelle nationale et renforce l'engagement de FMS en faveur de l'avancement des traitements de soins critiques.
Fresenius Medical Care (FMS) hat einen nationalen Gruppenbeschaffungsvertrag mit Premier, Inc. für sein Novalung ECMO-System abgeschlossen. Der Vertrag bietet den über 4.350 Mitgliedskrankenhäusern und Gesundheitssystemen von Premier Zugang zu vorverhandelten Preisen für das System, das von der FDA für die langfristige extrakorporale Membranoxygenierung zugelassen ist. Das Novalung-System pumpt und oxygeniert das Blut von Patienten mit akuter Atem- oder Herz-Lungen-Insuffizienz und bietet eine tragbare Therapie-Lösung für verschiedene klinische Umgebungen. Diese strategische Partnerschaft zielt darauf ab, den Zugang zu ECMO-Lösungen landesweit zu erweitern und bekräftigt das Engagement von FMS für die Weiterentwicklung der Intensivpflege-Behandlungen.
- Secured national purchasing agreement with Premier, gaining access to 4,350+ US hospitals
- First FDA-cleared system for long-term ECMO therapy
- Expands market reach for Novalung System through Premier's extensive healthcare network
- None.
Insights
The Premier agreement represents a significant commercial opportunity for Fresenius Medical Care's Novalung ECMO system. Access to Premier's network of 4,350+ hospitals substantially expands the potential market reach in the U.S. critical care segment. The ECMO market is experiencing strong growth due to increasing cases of acute respiratory and cardiac failure.
The pre-negotiated pricing terms through Premier will likely accelerate adoption by reducing procurement barriers and costs for member hospitals. As the first FDA-cleared long-term ECMO system, Novalung has a competitive advantage in a market where timing and reliability are crucial. The portable nature of the system adds flexibility for various clinical settings, potentially increasing its appeal to diverse healthcare facilities.
This agreement strengthens FMC's position in the critical care segment beyond its core dialysis business, representing a strategic diversification of revenue streams. The timing is opportune as hospitals seek efficient solutions for critical care management amid ongoing healthcare challenges.
- Strategic Relationship: Agreement expands access to ECMO solutions for hospitals, health systems and patients in the
U.S. nationwide. - Wide Reach: 4,350+ Premier member hospitals and health systems in the
U.S. can leverage pre-negotiated terms and pricing on the Novalung System for ECMO. - Commitment to Quality Care: Reinforces company's commitment to supporting healthcare providers in their efforts to deliver high-quality critical care treatments and solutions.
BAD HOMBURG,
"We are excited to be awarded this agreement by Premier, which will help broaden the reach of our Novalung ECMO System," said Olaf Schermeier, PhD, Chief Executive Officer, Critical Care & Ventures at Fresenius Medical Care. "This agreement highlights our dedication to delivering safe, simple, and portable solutions and enhancing patient outcomes in critical care units in
The Novalung System for extracorporeal membrane oxygenation (ECMO), was the first system FDA-cleared for long-term (>6hr) ECMO, providing a critical offering to patients and hospitals. The system pumps and oxygenates the blood of patients with acute respiratory failure or acute cardiopulmonary failure. Novalung offers a portable therapy solution designed to improve clinical outcomes and accommodate various clinical care settings such as intensive care units, operating rooms, cardiac catheterization labs and emergency departments.
Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,350
For more information about Fresenius Medical Care and the Novalung® System for ECMO, please visit https://fmcna.com/products/novalung-ecmo-therapy/novalung/.
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.1 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,732 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 308,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the company's website at www.freseniusmedicalcare.com.
Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the
Media contact
Kirsten Stratton
T +1 781 929 8096
kirsten.stratton@freseniusmedicalcare.com
Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com
Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2601
dominik.heger@freseniusmedicalcare.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-awarded-mechanical-circulatory-support-agreement-with-premier-inc-for-the-novalung-ecmo-system-302309872.html
SOURCE Fresenius Medical Care Holdings, Inc.
FAQ
What is the new agreement between Fresenius Medical Care (FMS) and Premier Inc?
What is the Novalung ECMO System by Fresenius Medical Care (FMS)?
How many hospitals will have access to FMS's Novalung System through the Premier agreement?
